GH Research (NASDAQ:GHRS) Shares Up 0.6% – Should You Buy?

GH Research PLC (NASDAQ:GHRS)’s stock price was up 0.6% during trading on Tuesday . The company traded as high as $8.10 and last traded at $8.05. Approximately 13,641 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 79,417 shares. The stock had previously closed at $8.00.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GHRS. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Thursday, September 5th. JMP Securities restated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Trading Up 0.9 %

The firm’s 50 day moving average is $7.96 and its two-hundred day moving average is $10.50. The stock has a market cap of $419.88 million, a price-to-earnings ratio of -12.01 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, equities analysts expect that GH Research PLC will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP grew its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the quarter. GH Research comprises approximately 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th largest position. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).